Aristides Capital’s CureVac CVAC Stock Holding History

Aristides Capital’s Portfolio CVAC Stock Details CVAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-23,777	Closed	-$100K	–	286
2023 Q4	$100K	Buy	+23,777	New	+$129K	0.04%	247

Other funds holding CVAC

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Aristides Capital's CVAC Position: Q1 2024 in Review

Aristides Capital sold out of CureVac (CVAC) in Q1 2024, closing a stake of 23,777 shares — an estimated $100K sold.

Aristides Capital first reported a position in CVAC in Q4 2023 and held it in 1 quarter. The position peaked at $100K in Q4 2023. 90 funds tracked by Wall St. Rank hold CVAC as of Q1 2024.

Aristides Capital reported no remaining CureVac position as of Q1 2024 after selling out during the quarter.
Aristides Capital sold 23,777 CureVac shares in Q1 2024, an estimated $100K.
Aristides Capital first reported a position in CureVac in Q4 2023 and held it in 1 quarter.
Aristides Capital's CureVac position peaked at $100K in Q4 2023.
90 funds tracked by Wall St. Rank held CureVac as of Q1 2024.

Based on Aristides Capital's 13F filing for Q1 2024, filed 15 May 2024.